第IVA期子宮頸癌檢視

Stage IVA cervical cancer

第IVA期子宮頸癌的定義為經切片或磁振造影診斷出在膀胱、和/或直腸的黏膜層有病灶的侵犯，發生率佔全部子宮頸癌1-5%。第IVA期子宮頸癌的5年存活率在5-50%。標準治療第IVA期子宮頸癌乃以cisplatin為主的化學放射線治療。最近，化學放射線治療採用磁振造影指引的腔內放射線治療，能有效和改善第IVA期子宮頸癌局部病灶的療效，同時對鄰近的器官傷害很少。更且，對已經同步化學放射線治療完成後，再以carboplatin合併paclitaxel的輔助治療，可能更能改善局部病灶的控制。

Stage IVA cervical cancer is defined by biopsy or MRI diagnosed involvement of the mucosa of the urinary bladder and/or rectum and accounts for 1-5% of all cervical cancers. The overall survival of stage IVA cervical cancer patients range from approximately 5-50% at five years. The standard treatment for stage IVA cervical cancer is chemoradiation with cisplatin, followed by brachytherapy. Recently, chemoradiotherapy and MRI based image-guided adaptive brachytherapy result in effective and improved local centrol of stage IVA cervical cancer, with a limited severe morbidity per organ. In addition, the adjuvant carboplatin and paclitaxel as consolidation chemotherapy following concurrent chemoradiotherapy seems to appear to improve control loco-regional lesion.